Q1: 2026-04-29 Earnings Summary
EPS of $1.29 beats by $0.02
|
Revenue of
$15.29B
(12.51% Y/Y)
beats by $356.99M
AstraZeneca PLC (AZN) Q1 2026 Earnings Call April 29, 2026 9:30 AM EDT
Company Participants
Joris Silon - Head of Investor Relations
Pascal Soriot - CEO & Executive Director
Aradhana Sarin - CFO & Executive Director
David Fredrickson - Executive Vice-President of Oncology Haematology Business Unit
Susan Galbraith - Executive Vice President of Oncology R&D
Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit
Sharon Barr - Executive Vice-President of BioPharmaceuticals R&D
Marc Dunoyer - CEO of Alexion & Chief Strategy Officer
Conference Call Participants
Richard Vosser - JPMorgan Chase & Co, Research Division
James Gordon - Barclays Bank PLC, Research Division
Sachin Jain - BofA Securities, Research Division
Graham Glyn Parry - Citigroup Inc., Research Division
Sarita Kapila - Morgan Stanley, Research Division
Rajan Sharma - Goldman Sachs Group, Inc., Research Division
Michael Leuchten - Jefferies LLC, Research Division
Matthew Weston - UBS Investment Bank, Research Division
Peter Verdult - BNP Paribas, Research Division
Christopher Uhde - SEB, Research Division
Seamus Fernandez - Guggenheim Securities, LLC, Research Division
Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division
Mattias Häggblom - Handelsbanken Capital Markets AB, Research Division
Simon Baker - Rothschild & Co Redburn, Research Division
Justin Steven Smith - Bernstein Institutional Services LLC, Research Division
Presentation
Operator
Good morning to those joining from the U.K. and the U.S. Good afternoon to those in Central Europe, and good evening to those listening in Asia. Welcome to AstraZeneca's Q1 2026 Webinar for Investors and Analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.
The company intends to utilize the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca. Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。